Category Archives: Other

OBJECTIVES: To assess HIV/AIDS research productivity in the 27 countries of the European Union (EU), and the structural level factors associated with levels of HIV/AIDS research productivity. METHODS: A bibliometric...

OBJECTIVE: Determine the sensitivity of rapid HIV tests (RT) compared to fourth generation enzyme immunoassays (EIA) or nucleic acid amplification tests (NAAT) in clinical settings. DESIGN: Systematic review and meta-analysis....

To estimate the nationwide and regional distribution of HIV-1 genotypes in China in the past three decades, province-specific HIV-1 molecular epidemiology data were derived from 260 independent studies of HIV...

CONTEXT: Smoking is responsible for increased morbidity and mortality in HIV-infected smokers OBJECTIVE:: To assess the efficacy of behavioral interventions for smoking cessation among HIV-infected smokers compared to the standard...

Human T-cell leukemia virus type 1 (HTLV-1), hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1) are prevalent worldwide, and share similar means of transmission. These infections may...

HIV infection is no longer characterized by high morbidity, rapid progression to AIDS, and death as when the infection was first identified. While anti-retroviral drugs have improved the outcome of...

Some HIV antiretroviral therapies (ART) have been associated with renal toxicities, which become of increasing concern as HIV-infected patients age and develop comorbidities. The objective of this study was to...

BACKGROUND: Viral load (VL) monitoring is the standard of care in developing country settings for detecting HIV treatment failure. Since 2010 the World Health Organization has recommended a phase-in approach...

BACKGROUND: The association between chemotactic chemokine ligand 5 (CCL5) -403G/A gene polymorphism and human immunodeficiency virus-1 (HIV-1) infection has been illustrated among several case-control studies, but the conclusions are still...

BACKGROUND: Single drug class regimens with nucleotide reverse transcriptase inhibitors (NRTIs) are generally not recommended as initial therapy, because they were inferior compared to therapy with 2 NRTIs plus efavirenz....

BACKGROUND: Approximately 28.5 million people living with HIV are eligible for treatment (CD4

HIV-1 enters the central nervous system by passing the blood-brain barrier during primary infection. Despite the introduction of combination antiretroviral therapy, the prevalence of HIV-associated neurocognitive disorders remains high and...